Photo from Nancy Lin/X
May 19, 2024, 05:46
Nancy Lin: Updated data for Pfizer cdk4-selective inhibitor PF-07220060
Nancy Lin, Associate Chief of Division of Breast Oncology at Susan F. Smith Center for Women’s Cancers, shared on X:
“Updated data for Pfizer cdk4-selective inhibitor PF-07220060.
- patient population: 100% prior cdk4/6i
- favorable tox profile
- 32% ORR, median PFS 8.1 months
- efficacy regardless of ESR1 and PIK3CA mutation status.”
Source: Nancy Lin/X
